Almalki AH, et al. - Via an observational study conducted including 96 adult patients with biopsy-proven focal or diffuse proliferative lupus nephritis (PLN) from four different hospitals, researchers assessed the rate of short-term remission and its influence on the long-term results of PLN in the Middle East. Mycophenolate mofetil (MMF), CYC, and other agents were used in 45/96, 41/96, and 10/96 of the cases. An elevation in recent years in the choice of MMF as an induction agent had been observed. The only histologic activity was discovered to have a notable correlation with remission, with active lesions more likely to remit than active/chronic and chronic lesions amongst baseline features. The 5-year renal survival rate without doubling serum creatinine was ascertained to be 73.8% on the basis of Kaplan–Meier analysis. Lower long-term renal survival rates were noted in cases with no remission and partial remission, in comparison with subjects with complete remission. At a 48-month median follow up, 23%, 11%, 10%, and 5% were the cumulative rate of doubling serum creatinine, dialysis, relapse, and death, respectively. Hence, in response to standard induction therapy, approximately two-thirds of subjects with PLN developed remission and remission had a negative correlation with the presence of chronic alterations in renal biopsy. MMF was the most frequently used agent for the induce remission, however, with more severe disease CYC, was used more commonly. Important long-term renal results including a 26% cumulative rate of doubling of serum creatinine at 5 years were correlated with PLN. Moreover, primary remission prognosticated this long-term renal survival.